RxDoctor Payments Data

Laura Dello Russo

Acute Care · Eatontown, NJNPI 1447426796

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 44 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$263
  • Novo Nordisk$213
  • AstraZeneca$158
  • Kestra Medical Technology Services, Inc.$139
  • Novartis$135
  • Boston Scientific$66
  • plus $291 from 10 others

What the payments were for

  • Food & beverage$1,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,265 in reported general payments places this provider in the 75th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,589
Medicare patients
407
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$28,695
EntrestoSacubitril/Valsartan11$12,820
Metoprolol Succinate81$1,132
Rosuvastatin Calcium65$1,129
Valsartan53$1,063
ClopidogrelClopidogrel Bisulfate95$966
Nebivolol Hcl27$936
Dofetilide11$726
Ezetimibe34$694
Hydralazine Hcl15$505
Carvedilol32$473
Atorvastatin Calcium53$418
Amlodipine Besylate73$398
Losartan Potassium25$304
Furosemide46$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$28,69534 claims
NovartisEntresto$135$12,82011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 656 acute care providers in New Jersey.

Other acute care in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →